The role of PAF/PAFR signaling in zymosan-induced articular inflammatory hyperalgesia
- 375 Downloads
Platelet-activating factor (PAF) and its receptor (PAFR) have been shown to be involved in several inflammatory events, including neutrophil chemoattraction and nociception. The present study addressed the role of PAF in the genesis of articular hyperalgesia in a model of joint inflammation. Zymosan-induced articular hyperalgesia, oedema and neutrophil migration were dose-dependently reduced following pretreatment with selective PAFR antagonists, UK74505 (5, 10 and 20 mg/kg) and PCA4248 (3, 10, 30 mg/kg). These parameters were also reduced in PAF receptor-deficient mice (PAFR−/−). The hyperalgesic action of PAF was further confirmed by the demonstration that joint injection of PAF induces a dose- (0.3, 1 and 3 μg/joint), time- and PAFR-dependent articular hyperalgesia and oedema. The PAF hyperalgesic mechanisms were dependent on prostaglandins, leukotrienes and neutrophils, as PAF-induced articular hyperalgesia was inhibited by indomethacin (COX inhibitor), MK886 (leukotrienes synthesis inhibitor) or fucoidan (leukocyte rolling inhibitor). Furthermore, PAF-induced hyperalgesia was reduced in 5-lypoxigenase-null mice. In corroboration of these findings, intra-articular injection of PAF promotes the production of LTB4 as well as the recruitment of neutrophils to the joint. These results suggest that PAF may participate in the cascade of events involved in the genesis of articular inflammatory hyperalgesia via stimulation of prostaglandins, leukotrienes and neutrophil migration. Finally, targeting PAF action (e.g., with a PAFR antagonist) might provide a useful therapeutic approach to inhibit articular inflammatory hyperalgesia.
KeywordsZymosan Joint pain Arthritis Hyperalgesia PAF Neutrophils
This work was supported by grants from Fundacão de Amparo à Pesquisa do Estado de São Paulo (FAPESP) and Conselho Nacional de Pesquisa (CNPq) in Brazil. We thank the excellent technical assistance of Ana K. dos Santos, Giuliana B. Francisco, Ieda Regina dos Santos Schivo and Sérgio R. Rosa.
- Howat D, Desa F, Chander C, Moore A, Willoughby DA (1990) The synergism between platelet-activating factor and interleukin-1 on cartilage breakdown. J Lipid Med 2:5143–5149Google Scholar
- Miguélez R, Palácios I, Navarro FA, Gutierrez S, Sanchez-Pernaute O, Egido J, Gonzalez E, Herrero-Beaumont G (1996) Anti-inflammatory effect of a PAF receptor antagonist and a new molecule with antiproteinase activity in an experimental model of acute urate crystal arthritis. J Lipid Mediat Cell Signal 13:35–49PubMedCrossRefGoogle Scholar
- Okubo M, Yamanaka H, Kobayashi K, Kanda H, Dai Y, Noguchi K (2012) Up-regulation of platelet-activating factor synthases and its receptor in spinal cord contribute to development of neuropathic pain following peripheral nerve injury. Mol Pain. doi: 10.1186/1744-8069-8-8
- Tsuda M, Ishii S, Masuda T, Hasegawa S, Nakamura K, Nagata K, Yamashita T, Furue H, Tozaki-Saitoh H, Yoshimura M, Koizumi S, Shimizu T, Inoue K (2007) Reduced pain behaviors and extracellular signal-related protein kinase activation in primary sensory neurons by peripheral tissue injury in mice lacking platelet-activating factor receptor. J Neurochem 102:1658–1668PubMedCrossRefGoogle Scholar
- Verri WA Jr, Cunha TM, Magro DA, Guerrero AT, Vieira SM, Carregaro V, Souza GR, Henriques MG, Ferreira SH, Cunha FQ (2009) Targeting endothelin ETA and ETB receptors inhibits antigen-induced neutrophil migration and mechanical hypernociception in mice. Naunyn-Schmiedebergs Arch Pharmacol 379:271–279PubMedCrossRefGoogle Scholar
- Zhang Q, Sitzman LA, Al-Hassani M, Cai S, Pollok KE, Travers JB, Hingtgen CM (2009) Involvement of platelet-activating factor in ultraviolet B-induced hyperalgesia. J Invest Dermatol 129:167–174Google Scholar